Primary Endpoints News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gannex s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Gannex s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongHong kong stock exchangePrnewswire gannex pharma company ltdGannex pharma co ltdSagimet biosciences incAscletis pharma incSagimet biosciencesPharma company ltdAscletis pharmaSignificance achievedPrimary endpointsSecondary endpointsArtificial intelligence

Sagimet Biosciences (SGMT) Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences (SGMT) Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Gannex pharma company ltdAscletis pharma incSagimet biosciences incAscletis pharmaSagimet biosciencesSignificance achievedPrimary endpointsSecondary endpointsArtificial intelligence

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis

United statesSagimet biosciencesMaria yonkoskiDave happelRohit loombaExchange commissionResearch centerSagimet biosciences incUniversity of california san diegoDivision of gastroenterologyChief executive officerCalifornia san diegoSignificance achievedPrimary endpointsSecondary endpointsArtificial intelligence

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16 9 Months and Median Overall Survival of 23 1 Months

Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society.

United statesUnited kingdomNew yorkFrance generalVictor morenoOmari vivarAnais debardValentin calugaruBrandon owensBernard dogerNathalie badoisAnne chillesEmiliano calvoLouis kayitalireXavier liemChristophe le tourneau

A Dab of MAB: Lecanemab, Aducanumab vs Standard of Care Treatment for Alzheimer Disease

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

United statesMckenzie erwinDuggan evansIwatsubot lecanemabLilly donanemabAshley sturmS budd haeberleinMayo clinic medical centerAlzheimer associationGuideline developmentDrug administrationClinical dementia rating sumPrimary endpointsAustin collegeClinical pharmacistMayo clinic medical